Q1 FY2026 Earnings
Financial report interval: 2025.12.31 - 2026.03.31
Overview: KalVista Pharma(KALV) the Revenue is 40.86 M (--%);the EBIT is -23.44 M (+52.84%);the EPS is -0.43 (+55.95%).
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
0.04B--
----
----
EBIT
-0.02B52.84%
----
----
EPS
-0.430355.95%
----
----
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf